Phase 1 dose-escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXaI16L ) - Parsons-Rich, D; Hua, F; Li, G; Kantaridis, C; Pittman, D D; Arkin, S (J Thromb Haemost, 2017)